Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 25.08.2021.

#biotech
#NBTintheNews
#covid
#deltavarient
#Jumpstart4Biotech
#psychedelic
#drugtrials
#pharmaceuticals

Companies And Industries

@NatureBiotech shared
On Aug 24, 2021
Kids’ nose cells are primed to fight viruses, may explain milder COVID-19 #NBTintheNews via @GENbio https://t.co/hoITJo0I1v
Open
Kids’ Nose Cells Are Primed to Fight Viruses, May Explain Milder COVID-19

Kids’ Nose Cells Are Primed to Fight Viruses, May Explain Milder COVID-19

The cells in children's airways are primed for sensing viruses, resulting in a strong early innate antiviral response to SARS-CoV-2 infection.

@biospace shared
On Aug 19, 2021
As Delta variant surges, more biopharma companies mandate COVID-19 vaccines #covid #deltavarient https://t.co/XOVSvoRXpb
Open
As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines

As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines

Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections. 

@Labiotech_eu shared
On Aug 23, 2021
The first step takes courage, find out today what @ThermoFisher’s Jump Start Program can do for you 👉🏻 https://t.co/IwI69VRuIk #Jumpstart4Biotech #biotech https://t.co/SAPzBvTlUh
Open
Start your new lab with Jump Start for Biotech

Start your new lab with Jump Start for Biotech

Jump Start for Biotech is a free program created to get your new lab up and running with products organized by therapeutic development and diagnostic workflows

@FierceBiotech shared
On Aug 23, 2021
The investigation was triggered by the results of a diversity, equity and inclusion survey that revealed “issues of particular concern in the Sabatini Lab.” Details of the specific allegations against Sabatini are yet to emerge https://t.co/yTBzOCfyNI
Open
Sabatini, biotech founder and mTOR pioneer, ousted after sexual harassment investigation

Sabatini, biotech founder and mTOR pioneer, ousted after sexual harassment investigation

David Sabatini, the scientific founder of several biotechs, has been ousted from his lab after a sexual harassment investigation. The high-profile cell signaling and cancer metabolism ...

@biospace shared
On Aug 19, 2021
Biotech company earns two patents for targeted delivery of psychedelic meds #biotech #psychedelic https://t.co/UvQbXp4Wdz
Open
Biotech Company Earns Two Patents for Targeted Delivery of Psychedelic Meds

Biotech Company Earns Two Patents for Targeted Delivery of Psychedelic Meds

Psycheceutical Inc. was issued two patents by the United States Patent and Trademark Office for what it calls a “precision duplicity” approach to delivering psychedelic drugs to patients.

@matthewherper shared
On Aug 21, 2021
Biotech founder David Sabatini placed on leave after harassment probe. https://t.co/Z9oIEn9eyf
Open
Biotech founder David Sabatini placed on leave following investigation into sexual harassment

Biotech founder David Sabatini placed on leave following investigation into sexual harassment

The prominent biology professor and biotech founder at MIT has been accused of sexual harassment and placed on administrative leave.

@biospace shared
On Aug 24, 2021
Theravance drug candidate for ulcerative colitis fails to meet primary endpoint #drugtrials #pharmaceuticals https://t.co/ZY2xTYwXZa
Open
Theravance Drug Candidate for Ulcerative Colitis Fails To Meet Primary Endpoint

Theravance Drug Candidate for Ulcerative Colitis Fails To Meet Primary Endpoint

​Izencitinib was generally well tolerated and its safety data were consistent with expectations, but it failed to achieve its primary endpoint of seeing a change in the total Mayo score at ...

@FierceBiotech shared
On Aug 20, 2021
Analysts at Jefferies noted the “high expectations” going into the readout, and, while it saw “strong data,” there will “still be investor questions coming away from this week on the durability of '516 and '596.” https://t.co/3Mxnj2lFYP
Open
Despite upbeat tones from analysts, Fate Therapeutics' stock drops on blood cancer readout

Despite upbeat tones from analysts, Fate Therapeutics' stock drops on blood cancer readout

Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop.